Anticoagulant
16
1
2
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.3%
1 terminated out of 16 trials
85.7%
-0.8% vs benchmark
19%
3 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (16)
Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
Study of Low Molecular Weight Heparins
Management of Venous Thromboembolism in France: a National Survey Among Vascular Medicine Physicians
Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration
Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care
A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers
A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344
A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition
A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity
Determinants of Oral Anticoagulants' Activity
Evaluation of Patient's Knowledge of Their NACO Treatment